Literature DB >> 15852062

Wolframin mutations and hospitalization for psychiatric illness.

M Swift1, R G Swift.   

Abstract

Genetic predisposition plays an important role in most common psychiatric disorders. The identification of a specific gene associated with a psychiatric illness can lead to improved management of the gene-associated disorder. Mutations in the wolframin gene are associated with mental illness. Many patients with the Wolfram syndrome (WS), who are homozygous or compound heterozygous for wolframin mutations, have severe psychiatric symptoms. In WS families, close blood relatives, who have a high probability of carrying a single wolframin mutation, had a statistically significant excess, over spouse controls, of psychiatric hospitalizations, attempted and completed suicides, and self-reports of mental illness. Since heterozygous carriers of wolframin mutations are relatively frequent in the population according to the general Hardy-Weinberg principle, such mutations might be responsible for the illnesses of many psychiatric patients. The hypothesis that heterozygous carriers of a wolframin mutation are predisposed to psychiatric illness was tested in subjects from 25 WS families. In all, 11 relatives who had psychiatric hospitalizations could be genotyped through mutation analysis. Eight of these carried the wolframin mutation transmitted in their family, significantly (one-sided P=0.0022) more than the 3.0 expected if there were no association between psychiatric hospitalizations and mutations at this locus. All eight mutation-positive subjects had been hospitalized for a major depression. This confirmation of the association is not influenced by confounders, undetected stratification, or genetic heterogeneity. The relative risk of psychiatric hospitalization for depression was estimated to be 7.1 (95% CI 1.9-26.6) for carriers of a single wolframin mutation compared to noncarriers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852062     DOI: 10.1038/sj.mp.4001681

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  22 in total

1.  Wolfram syndrome: clinical and genetic profiling of a cohort from a tertiary care centre with characterization of the primary gonadal failure.

Authors:  Liza Das; Ashutosh Rai; Ravimohan Mavuduru; Kim Vaiphei; Akhilesh Sharma; Vishali Gupta; Sanjay Kumar Bhadada; Sailesh Lodha; Naresh Panda; Anil Bhansali; Paramjeet Singh; Pinaki Dutta
Journal:  Endocrine       Date:  2020-04-29       Impact factor: 3.633

Review 2.  Endocrine and metabolic aspects of the Wolfram syndrome.

Authors:  Georgios Boutzios; Sarantis Livadas; Evangelos Marinakis; Nicole Opie; Frangiskos Economou; Evanthia Diamanti-Kandarakis
Journal:  Endocrine       Date:  2011-08       Impact factor: 3.633

3.  Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells.

Authors:  Sonya G Fonseca; Shinsuke Ishigaki; Christine M Oslowski; Simin Lu; Kathryn L Lipson; Rajarshi Ghosh; Emiko Hayashi; Hisamitsu Ishihara; Yoshitomo Oka; M Alan Permutt; Fumihiko Urano
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

4.  Autoimmune disease in a DFNA6/14/38 family carrying a novel missense mutation in WFS1.

Authors:  Michael S Hildebrand; Jessica L Sorensen; Maren Jensen; William J Kimberling; Richard J H Smith
Journal:  Am J Med Genet A       Date:  2008-09-01       Impact factor: 2.802

5.  Wolframin gene H611R polymorphism: no direct association with suicidal behavior but possible link to mood disorders.

Authors:  Gil Zalsman; Mark J Mann; Yung-Yu Huang; Maria A Oquendo; David A Brent; Ainsley K Burke; Steven P Ellis; J John Mann
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-03-26       Impact factor: 5.067

6.  Gene expression changes in the prefrontal cortex, anterior cingulate cortex and nucleus accumbens of mood disorders subjects that committed suicide.

Authors:  Adolfo Sequeira; Ling Morgan; David M Walsh; Preston M Cartagena; Prabhakara Choudary; Jun Li; Alan F Schatzberg; Stanley J Watson; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

7.  Prohormone convertase 2 activity is increased in the hippocampus of Wfs1 knockout mice.

Authors:  Karin Tein; Sergo Kasvandik; Sulev Kõks; Eero Vasar; Anton Terasmaa
Journal:  Front Mol Neurosci       Date:  2015-08-25       Impact factor: 5.639

8.  Layer 2/3 pyramidal cells in the medial prefrontal cortex moderate stress induced depressive behaviors.

Authors:  Prerana Shrestha; Awni Mousa; Nathaniel Heintz
Journal:  Elife       Date:  2015-09-15       Impact factor: 8.140

9.  Wfs1-deficient mice display altered function of serotonergic system and increased behavioral response to antidepressants.

Authors:  Tanel Visnapuu; Sirli Raud; Maarja Loomets; Riin Reimets; Silva Sütt; Hendrik Luuk; Mario Plaas; Sulev Kõks; Vallo Volke; Aet Alttoa; Jaanus Harro; Eero Vasar
Journal:  Front Neurosci       Date:  2013-07-31       Impact factor: 4.677

10.  Valproate, a mood stabilizer, induces WFS1 expression and modulates its interaction with ER stress protein GRP94.

Authors:  Chihiro Kakiuchi; Shinsuke Ishigaki; Christine M Oslowski; Sonya G Fonseca; Tadafumi Kato; Fumihiko Urano
Journal:  PLoS One       Date:  2009-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.